Additionally, OPRM1 is targeted by naltrexone, which is FDA-approved for treating AUD and opioid use disorder, and as a combination drug, naltrexone-bupropion, for the treatment of obesity19,76 Importantly, both the PDE4B and OPRM1 loci exhibited concordant effects on AUD and BMI. Here, OPRM1 is linked to opioid use disorder.